8.01

5.12% 0.39

After Hours: 8.02 0.010 +0.12%

Diamedica Therapeutics Inc (DMAC)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Diamedica Therapeutics Inc stock is traded at $8.01, with a volume of 478.53K. It is up +5.12% in the last 24 hours and up +42.02% over the past month. DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Previous Close:

$7.62

Open:

$7.65

24h Volume:

478.53K

Relative Volume:

2.43

Market Cap:

$431.61M

Revenue:

Net Income/Loss:

$-35.10M

P/E Ratio:

-11.36

EPS:

-0.7051

Net Cash Flow:

$-31.49M

1W Performance:

+10.94%

1M Performance:

+42.02%

6M Performance:

-5.99%

1Y Performance:

+113.03%

1-Day Range:

$7.65

$8.525

1-Week Range:

$6.98

$8.525

52-Week Range:

$3.57

$10.42

Diamedica Therapeutics Inc Stock (DMAC) Company Profile

Name

Diamedica Therapeutics Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

(763) 496-5454

Address

301 CARLSON PARKWAY, MINNEAPOLIS, MN

Employee

Twitter

@diamedica

Next Earnings Date

2026-08-11

Latest SEC Filings

DMAC's Discussions on Twitter

Compare DMAC vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DMAC Diamedica Therapeutics Inc	8.01	379.34M	0	-35.10M	-31.49M	-0.7051
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-14-25	Resumed	Cantor Fitzgerald	Overweight
Oct-30-25	Initiated	TD Cowen	Buy
Oct-07-24	Initiated	H.C. Wainwright	Buy
Apr-24-24	Resumed	Craig Hallum	Buy
Jun-22-23	Upgrade	Oppenheimer	Perform → Outperform
Apr-09-21	Initiated	Oppenheimer	Outperform
Feb-17-21	Initiated	ROTH Capital	Buy
Oct-30-20	Initiated	Guggenheim	Buy
Jul-08-20	Initiated	Maxim Group	Buy
Apr-30-19	Initiated	Dougherty & Company	Buy
Mar-05-19	Initiated	Lake Street	Buy

View All

Diamedica Therapeutics Inc Stock (DMAC) Latest News

Jun 26, 2026

DiaMedica Therapeutics (DMAC) Short Interest & Short Float | Updated Jun 2026 - MarketBeat

Jun 25, 2026

Jun 24, 2026

DiaMedica Therapeutics Up 10%, Insider Buyers Are Up 43% - simplywall.st

Jun 24, 2026

DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction - BioSpace

Jun 24, 2026

Jun 23, 2026

DiaMedica Therapeutics (DMAC) Initiates Phase 2 Trial for DM199 in Fetal Growth Restriction - GuruFocus

Jun 23, 2026

DiaMedica doses first patients in fetal growth restriction trial - Investing.com

Jun 23, 2026

Jun 18, 2026